Wu, Qing-Juan
Lv, Wen-Liang http://orcid.org/0000-0002-4552-919X
Li, Juan-Mei
Zhang, Ting-Ting
Zhou, Wen-hui
Zhang, Qiang
Wang, Jiu-Chong
Wang, Qing-Nan
Zhang, Ruo-Xuan
Zhao, Xin
Chen, Si-Tong
Liu, Shuang
Li, Gao-Hui
Cao, Zheng-Min
Xu, Lei
Chen, Jing
Funding for this research was provided by:
Key Technologies Research and Development Program (2018YFC1705700)
Article History
Received: 18 December 2019
Accepted: 8 May 2020
First Online: 5 June 2020
Ethics approval and consent to participate
: The protocol has been approved by the Medical Ethics Committee of Hangzhou Xixi Hospital, China (for central ethical approval), and the other centers in the trial will not begin recruiting until local ethical approval has been obtained. All study participants will sign two informed consent forms, one kept by the patients and the other kept by the researcher. The results of this study will be published in a peer-reviewed journal.
: According to the terms of the informed consent, unless the subject’s consent is obtained, all the subject’s personal information is confidential and will not be disclosed to the public. When it is necessary, the drug supervision and administration department, ethics committee, or project funding department may consult the subject’s data. Without permission, they will not use the subject’s information for other purposes or disclose it to other groups.
: The authors declare that they have no competing interests.